MARKET

KROS

KROS

Keros Therapeutics, Inc.
NASDAQ
9.94
-0.27
-2.64%
Opening 10:03 07/28 EDT
OPEN
10.26
PREV CLOSE
10.21
HIGH
10.42
LOW
9.91
VOLUME
10.47K
TURNOVER
--
52 WEEK HIGH
22.55
52 WEEK LOW
9.69
MARKET CAP
196.73M
P/E (TTM)
-3.3036
1D
5D
1M
3M
1Y
5Y
1D
Incyte (INCY) Q2 Earnings and Revenues Top Estimates
NASDAQ · 1h ago
Weekly Report: what happened at KROS last week (0720-0724)?
Weekly Report · 1d ago
Keros Therapeutics CFO Keith Regnante Resigns, Effective Aug. 3; VP Finance Annita Tanini Named Interim Principal Financial Officer
Benzinga · 5d ago
Keros Therapeutics Announces CFO Resignation and Interim Successor
TipRanks · 5d ago
KEROS THERAPEUTICS - APPOINTS ANNITA TANINI INTERIM PRINCIPAL FINANCIAL OFFICER EFFECTIVE AUGUST 4, 2026 - SEC FILING
Reuters · 5d ago
Keros Therapeutics names Annita Tanini interim CFO as Keith Regnante resigns
PUBT · 5d ago
Monday 7/20 Insider Buying Report: NVA, KROS
NASDAQ · 07/20 19:38
Weekly Report: what happened at KROS last week (0713-0717)?
Weekly Report · 07/20 10:01
More
About KROS
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Webull offers Keros Therapeutics Inc stock information, including NASDAQ: KROS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KROS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KROS stock methods without spending real money on the virtual paper trading platform.